



Atty. Docket No.: 8039/1122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Tomlinson  
Serial No.: 09/888,313  
Filed: June 22, 2001  
Entitled: Matrix Screening Method

Examiner: Tran, My Chau  
Group Art Unit: 1639  
Conf. No.: 9556

REC-1639  
SEP 25 2003  
PATENT  
10/1/03

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF PRIORITY DOCUMENT**


Dear Sir:

As required by 35 U.S.C. 119(b), Applicants submit herewith a certified copy of UK 0015443.5 and 0026099.2, from which the above-referenced patent application claims priority.

Date: September 17, 2003

Respectfully submitted,

Name: Kathleen M. Williams  
Registration No.: 34,380  
Customer No.: 29933  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100





INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the application is now proceeding in the name as identified herein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Stephen Hordley*

Dated 2 September 2003





INVESTOR IN PEOPLE


GB0015443.5


By virtue of a direction given under Section 30 of the Patents Act 1977, the application is proceeding in the name of

DIVERSYS LIMITED,  
20 Park Crescent,  
LONDON,  
W1N 4AL,  
United Kingdom

Incorporated in the United Kingdom

[ADP No. 08006595001]





The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

# Request for a grant of a patent

(See the notes on the back of this form you can also get an explanatory leaflet from the Patent Office to help you fill in this form)

23 JUN 2000

1. Your reference

P008091GB ATM

26JUN00 E547612-1 D02246

P01/7700 0.00-0015443.5

2. Patent application number  
(The Patent Office will fill in this part)

**0015443.5**

3. Full name, address and postcode of the  
or of each applicant  
(underline all surnames)

Medical Research Council  
20 Park Crescent  
London  
W1N 4AL  
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give  
the country/state of its incorporation

United Kingdom

596007001

4. Title of the invention

Matrix Screening Method

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

21 NEW FETTER LANE  
LONDON  
EC4A 1DA

Patents ADP number (if you know it)

59006

6. If you are declaring priority from  
one or more earlier patent  
applications, give the country and  
date of filing of the or each of these  
earlier applications and (if you know  
it) the or each application number

1st

2nd

3rd

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and filing date of the  
earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent

required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document	Continuation sheets of this form	0
	Description	22
	Claim(s)	5
	Abstract	1
	Drawing(s)	3
10. If you are also filing any of the following, state how many against each item	Priority Documents	0
	Translation of Priority Documents	0
	Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
	Request for preliminary examination and search (Patents Form 9/77)	0
	Request for substantive examination (Patents Form 10/77)	0
	Any other documents (Please specify)	0

11.

I/We request the grant of a Patent on the basis of this application.

Signature

Date

*D. Young & Co.*

**D YOUNG & CO**

Agents for the Applicants

23 Jun 2000

12. Name and daytime telephone number of person to contact in the United Kingdom	Antonio Maschio	023 80634816
--	-----------------	--------------

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) if there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheets should be attached to this form.

d) If you answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.



## Matrix Screening Method

The present invention relates to a method which can be used to screen two or more repertoires of molecules against one another and/or to create and screen combinatorial repertoires by combining two or more repertoires. In particular, the invention relates to a method whereby two repertoires of molecules can be screened such that all members of the first repertoire are tested against all members of the second repertoire for functional interactions. Furthermore, the invention relates to the creation and screening of antibody repertoires by combining a repertoire of heavy chains with a repertoire of light chains such that antibodies formed by the all combinations of heavy and light chains can be screened against one or more target ligands.

### Introduction

The mapping and sequencing of different genomes will eventually lead to the cloning of all the proteins expressed by these organisms. In order to create interaction maps of these proteins, two-dimensional screens need to be performed so that the binding of every protein to every other protein can be tested.

Two dimensional screens are also required for a number of other applications. For example, techniques such as mouse immunisation coupled with the production of monoclonal antibodies and *in vitro* selection methods such as phage display have been used to simultaneously generate many different antibodies against many different targets. In order to determine which antibodies bind to which targets these pools need to be deconvoluted, which requires a complex screening procedure.

Furthermore, if small molecule drugs are to be generated against human targets for therapy it would be helpful to determine not only the extent of binding of a given human protein to a putative drug candidate but also the extent (if any) of cross-reaction of the same drug candidate with other human proteins or whether other related drugs are better binders and/or less cross-reactive.

All of these examples call for a technique whereby interactions between members of a first set (or repertoire) of molecules can be rapidly tested against all members of a second set (or repertoire) of molecules. To date, such screens are generally performed by dispensing combinations of reagents into compartmentalised wells or on top of one another in the form of spots on a membrane such that all combinations of reagents to be tested are present in separate wells/spots. Therefore if a repertoire of 100 molecules were to be tested against a different repertoire also consisting of 100 molecules, 10,000

wells/spots would be required to exhaustively cover all combinations of members of the two repertoires. The creation of such discontinuously arranged combinations would require, for a two component interaction, twice as many dispensing 'events' as there are wells or spots, in this case 20,000, in addition to any dispensing events that might be required to facilitate or detect the interactions. As the number of members in each repertoire increases linearly, the number of combinations, and hence dispensing events, increases exponentially. Indeed for a three component interaction, involving, say, a repertoire of only 100 antibody heavy chains, a repertoire of only 100 antibody light chains and a repertoire of only 100 potential antigens, a million 'dispensing' events would be required.

### Summary of the Invention

We have developed a methodology, which we have called Matrix Screening, which can be used to study all possible interactions between all the members in two repertoires of molecules which removes the need to compartmentalise individual combinations of members of these repertoires.

According to a first aspect of the present invention, there is provided a method for screening a first repertoire of molecules against a second repertoire of molecules to identify those members of the first repertoire which interact with members of the second repertoire, comprising :

- (a) arranging the first and second repertoires to form at least one array, such that all members of the first repertoire are juxtaposed to all members of the second repertoire; and
- (b) detecting the interaction/s between the members of the first and second repertoires.

The invention, in its broadest form, provides a method for screening two repertoires of molecules against one another. Individual members of the two repertoires are spatially configured to enable the juxtaposition of all combinations of members of both repertoires. It will be understood that reference herein to "all combinations" (or "all members") does not exclude that certain juxtapositions may not occur, either by chance or by design. However, the invention does require that two repertoires of molecules be screened against each other simultaneously, and excludes the screening of a single repertoire with individual member(s) of a second repertoire.

According to the invention, juxtaposition may be arrived at by, for example, creating a series of lines for each of the two repertoires, which intersect one another. The lines may be straight, substantially parallel lines, or curves, or combinations thereof; the only restriction is that all members of the first repertoire should be able to interact all members  
5 of the second repertoire. Examples of complementary configurations include straight parallel lines, disposed at an angle to straight parallel lines; concentric circles or polygons, used together with a star of radial lines. The skilled person will be able to imagine many other systems being used to achieve a similar spatial configuration of the repertoire members according to the invention, all being characterised by the dispensation  
10 of some form of continuous line, stream, channel or flow corresponding to each member of the first repertoire, all of which has the ability to intersect all lines, streams, channels or flows corresponding to all members of the second repertoire. These include tubes for each member of the first repertoire which intersect tubes of the second repertoire, or channels cut in a solid material down which individual repertoire members can flow.

15 Therefore, according to a second aspect of the invention, there is provided a method wherein members of the both the first repertoire and the second repertoire are arranged in a series of lines, channels or tubes, each containing a member of the first or second repertoires such that the lines, channels or tubes corresponding to the first repertoire and  
20 those corresponding to the second repertoire are contacted with one another so that all members of the first repertoire are juxtaposed with all members of the second repertoire.

In the context of the present invention, "a" member may mean one single member or at least one member. Advantageously, it refers to one single member. However, in an  
25 alternative aspect the invention also provides the use of groups consisting of more than one member of the repertoire in each line, channel or tube. Preferably, such groups consist of 10 or fewer members, advantageously 5 or fewer, but at least 2.

The advantage of using intersecting lines, channels, streams or flows according to the  
30 present invention compared to compartmentalised combinatorial screening in the prior art is that as the size of the individual repertoires grow linearly, so does the number of dispensing steps required to screen all combinations of repertoire members. Thus, whereas screening techniques using wells would require 10,000 dispensing steps to screen a 100 by 100 repertoire, screening according to the present invention requires only 200  
35 dispensing steps. Furthermore, since a single dispensing event is used to spatially array each member of each repertoire, comparison of interactions between individual members of the first repertoire with the members of the second repertoire with which it is juxtaposed will be more accurate. In addition, since the present invention uses

intersecting lines rather than spots or intersecting channels rather than wells, less positional accuracy is necessary to ensure that all combinations of possible interactions are tested. Thus, if a two-dimensional screen is performed, and one line corresponding to a member of the first repertoire is offset by, for example, 1mm, since it is arranged at an angle to all the lines from the second repertoire, it will still intersect all of them and therefore all combinations of interactions will still have been successfully tested. If, on the other hand, the spots corresponding to a member of the first repertoire are offset by, for example, 1mm, they may miss the spots corresponding to the members of the second repertoire altogether and therefore many combinations of interactions will not have been tested. Therefore, the present invention is not only well suited to automated methods of screening but also to manual methods, where positional accuracy cannot be guaranteed and the number of dispensing events must be limited.

As described above, the lines, channels or tubes may be arranged in a variety of formats and may be arranged on a single support, or a plurality of supports. In the simplest configuration, molecules may be manually drawn out in the form of lines on a single support, for example on a nitrocellulose membrane. These lines may also be applied to suitable supports using robotic techniques, which allow the accuracy and density of arrays to be increased to great advantage in the present invention. In an advantageous aspect of the invention, a multi-support system may be used, wherein arrays of lines are prepared on separate supports which are then juxtaposed in order to assess interaction between the members of the repertoires.

Accordingly, in a third aspect of the invention a method is provided for screening a first repertoire of molecules against a second repertoire of molecules to identify one or more members of the first repertoire which interact with one or more members of the second repertoire, comprising :

- (a) arranging the first and second repertoires on first and second supports;
- (b) juxtaposing the first and second supports such that all members of the first repertoire are juxtaposed with all members of the second repertoire; and
- (c) detecting the interactions between the members of the first and second repertoires.

The present invention can also be applied to higher dimensional arrays, for example, those with 3 dimensions. Thus, three component interactions, such as enzyme, substrate and co-factor can be screened using lines, channels or tubes that are arranged in 3 dimensions. Alternatively, the three components could be antibody heavy chain, antibody light chain and antigen, and repertoires thereof can be screened in three dimensions. The screening of repertoires in 2, 3 or higher dimensions according to the present invention is

highly advantageous as it reduces the number of dispensing (or pipetting) events that would be required to perform a comprehensive combinatorial screen. Thus, the screening of two repertoires, of, say, 300 members against one another using conventional techniques in the prior art would require at least 90,000 separate dispensing events and the screening of three repertoires, of, say, 300 members against one another would require at least 2.7 million dispensing events. By contrast, the present invention reduces the number of dispensing events to comprehensively screen the same repertoires to 600 or 900, respectively, a huge saving in terms of time and labour.

According to a fourth aspect of the present invention, therefore, there is provided a method for screening first, second and third repertoires of molecules against each other to identify those members of the first, second and third repertoires which interact, comprising :

- (a) arranging the first, second and third repertoires to form at least one array, such that all members of the first, second and third repertoires are juxtaposed; and
- (b) detecting the interaction/s between the members of the first, second and second repertoires.

A multidimensional array may be created in a number of ways. Advantageously, a third dimension is created by stacking filters or other such membranes and relying on capillary action for transferring molecules, or by forcing molecules through the stack by a means such as electrophoresis or osmosis or by piercing the stack or by the use of permeable filters to create the stack.

Moreover, a third dimension may be created by stacking non-permeable layers which at the intersections of channels (for the first and second repertoires) have holes which (once the layers are stacked) form an additional set of channels in a third dimension along which members of a third repertoire can pass.

In a further embodiment, the third dimension may be created using a block of gel or similar such substance, which can be injected with members of the first, second and third repertoires along the x, y and z faces, respectively, thus creating channels in a three-dimensional space which form the array.

Still further, the matrix of interactions between members of the first, second (and optionally third) repertoires of molecules can be created using a network of intersecting tubes or semi-permeable tubes laid adjacent to one another.

The members of the first, second (and optionally third) repertoires of molecules can be replaced over time with different members from the same repertoires so that a new combination or set of interactions can be screened.

- 5 Since the present invention can be used to rapidly screen multicomponent and multi-chain interactions, it can also be applied to the simultaneous creation and screening of combinatorial libraries of molecules, for example, antibody or T cell receptor libraries. Thus instead of generating a large combinatorial library of antibodies by combining the heavy and light chain genes and then separately screening the resulting pairings, the
- 10 pairings themselves can be generated according to the invention and, optionally screened against one or more target antigens. Thus, say, 1000 heavy chains could be drawn as lines in one dimension, and a 1000 light chains can be drawn as lines in another, such that all the heavy chain lines intersect all the light chain lines, forming at their intersection fully functional and folded antibody molecules, which can then be screened with a juxtaposed
- 15 antigen, for example coated on a further support which is brought into contact with the intersecting heavy and light chain lines. According to this embodiment, all combinations of 1000 heavy chains and 1000 light chains will have been screened i.e. a total of 1 million different antibodies, using only 2000 dispensing events, rather than the 1 million that would have to be used according to screening techniques in the prior art. This
- 20 provides a rapid way for 'naive' screening for specific interactions. Thus, for example, a repertoire of heavy chains and a repertoires of light chains, the members (or any related member) of which have never been in contact or selected against a given target antigen (or a related target antigen thereof) can be screened against the target antigen to identify a specific binding heavy and light chain pairing.

25

Thus, in a fifth aspect of the present invention a method is provided for creating and screening a combinatorial library of two-chain polypeptides, each of which comprises one member of a first repertoire and one member of a second repertoire, which method comprises:

- 30 (a) arranging the first and second repertoires to form at least one array, such that all members of the first repertoire are juxtaposed to members of the second repertoire, thereby generating at their juxtapositions all combinations of functional two-chain polypeptides; and optionally
- (b) detecting the interaction between the two-chain polypeptides and a target
- 35 molecule.

Preferably, the combinatorial library is an antibody or T cell receptor library and the two repertoires consist of heavy and light chains (in the case of an antibody library) or alpha and beta chains (in the case of a T cell receptor library).

5 The combinatorial library so produced is preferably screened for interactions with more than one target molecule. Thus, the target molecule may be provided in the form of a group of target molecules, or a repertoire thereof, and screened in a three-dimensional array as described herein.

10 Preferably, the method according to the invention may be used such that a three-chain polypeptide library is created (and optionally screened) using first, second and third repertoires of molecules in three dimensions.

The pattern of interactions between the first, second (and optionally third) repertoires may  
15 be used to identify positive interactions, negative interactions, specific interactions or cross-reactive interactions, or to construct a phylogenic tree inferring the similarity between members of the first repertoire (using the pattern of interactions with the second and/or, optionally third, repertoires), of the second repertoire (using the pattern of interactions with the first and/or, optionally third, repertoires) and/or of the third  
20 repertoire (using the pattern of interactions with members the first and/or second repertoires).

Since many of the interactions that will be screened according to the present invention involve polypeptides that have been derived, directly or indirectly, by expression of  
25 nucleic acid sequences, it is highly advantageous that the nucleic acids themselves are arranged in lines, channels or tubes according to the invention and expressed to produce their corresponding polypeptides. In this way, intersecting polypeptides from each of the two repertoires will be expressed together. This may assist their association, particularly when the association of the two repertoire members depends on co-operative folding, for  
30 example, as in the case of antibodies. In addition, information regarding the interactions of members of the repertoires will be spatially linked to the genetic information which encodes them. This genetic information can be determined by calculating the co-ordinates of the interaction and isolating the corresponding nucleotide sequence data from any point on its line, channel or tube or by isolating the nucleotide sequence data from the  
35 intersection itself.

Accordingly, in a sixth aspect of the present invention, a method is provided whereby one or more of the first, second and, optionally, third repertoires comprise a plurality of

nucleic acid molecules which are expressed to produce their corresponding polypeptides *in situ* in the array.

5 Since the present invention concerns the rapid and efficient screening of two or more  
repertoires against one another, any currently employed techniques for enhancing or  
disrupting molecular interactions can be used with the invention. Thus, one repertoire  
may consist of variants of a free hapten and the other repertoire may consist of selected  
anti-hapten antibodies. By arranging both repertoires in close proximity to an  
10 immobilised version of the target hapten molecule the screen can be used to identify those  
antibodies that are competed for binding to the immobilised target hapten by binding to  
certain free hapten variants. In this case, the lack of binding would be considered a  
positive result. Controls for such an experiment may include a line of water alongside the  
free haptens and a line of non-hapten binding antibodies alongside the anti-hapten  
15 antibodies. Alternatively, a single free hapten could be used to disrupt binding of  
members of a repertoire of anti-hapten antibodies to members of a repertoire of different  
immobilised hapten variants. Other third molecules might include substances that  
enhance binding of the repertoire members to one another, which may be used itself in the  
form of a repertoire according to the invention. In this way, a target molecule could be  
20 immobilised on a solid support and intersecting repertoires of binders and binder  
enhancers could be brought into contact with the target molecule. Those skilled in the art  
will envisage many different combinations of such molecules and repertoire members.

Accordingly, in a seventh aspect of the present invention a method is provided for  
screening a first repertoire of molecules against a second repertoire of molecules to  
25 identify members of the first and second repertoires whose interactions with one another  
are dependant on the presence or absence of a third molecule or set of molecules,  
comprising:

- (a) arranging the first and second repertoires to form at least one array, such that all  
members of the first repertoire are juxtaposed with all members of the second repertoire;  
30 and
- (b) detecting the interactions between members of the first repertoire and the  
members of the second repertoire in the presence of different concentrations of the third  
molecule or set of molecules.

35 The method of the present invention bridges the gap between the initial identification of  
lead targets and molecules from very large repertoires and the final identification of  
targets or drugs for therapeutic intervention. This problem is addressed in the prior art by  
use of ELISA screening of possible positive interactants. However, protocols for ELISA



are not easily automated for high throughput. The highly parallel nature of the method according to the present invention will reveal comprehensive interaction profiles for members of each repertoire. This will enable, for example, ligands that interact with an entire family of proteins to be distinguished from those which react with only a subset of that family, cross-reactive drugs to be eliminated from development programmes, and the true specificity and cross-reactivity of antibodies to be determined. The determination of an antibodies cross-reactivity and hence its specificity is of vital importance where there is a panel of different antibodies have been derived from an immunized mouse or from an *in vitro* selections performed, for example, by phage display. Matrix Screening is particularly powerful in this context as it enables a comprehensive range of antigens to be tested against each antibody in the panel, minimising the chance of unknown and unwanted cross reactivities disrupting downstream investigations.

Alternatively, by using the present invention to create and screen large comprehensively combinatorial libraries, one million clone antibody libraries could be created and screened using only 2,000 dispensing events. In addition, complex protein-protein interaction maps can be created from enriched sources of interacting pairs, or possibly using entire proteomes together with very high density matrices according to the invention.

The invention also incorporates the key advantages of phage display and other expression-display techniques, namely that the nucleic acids encoding the members of a polypeptide repertoire can be spatially associated with their corresponding polypeptides and can thus be selected on the basis of the functional characteristics of the individual polypeptide. Unlike phage display, however, in which this association is achieved by compartmentalising the nucleic acids and the polypeptides using bacterial cells which display the polypeptides on their surfaces, the subject invention advantageously exploits a novel arraying strategy to provide this association. By eliminating the requirement for the nucleic acids and the polypeptides to be retained in or on bacterial cells, the present invention may be extended beyond selection of binding activities to select any polypeptide repertoire on the basis of any functional property of the polypeptides, including enzymatic activity, conformation or any other detectable characteristic.

Various apparatus may be supplied in association with reagents or tools for performing the screens described above.

## Definitions

The term "repertoire" as used according to the present invention refers to a population of diverse variants, for example polypeptide variants which differ in amino acid sequence, DNA variants that differ in nucleotide composition and/or sequence or any other type of molecule which can exist in a number of different forms. Generally, a repertoire includes more than 10 different variants. Large repertoires comprise the highest number of possible variants for selection and can be up to  $10^{13}$  in size. Smaller repertoires are particularly useful, especially if they have been pre-selected to enrich for a particularly useful subset (for example, antibodies that bind cell surface markers, enzymes that catalyse a certain set of reactions, proteins that bind to other proteins etc) or to remove unwanted members (such as those including stop codons, incapable of correct folding or which are otherwise inactive). Such smaller repertoires may comprise  $10$ ,  $10^2$ ,  $10^3$ ,  $10^4$ ,  $10^5$ ,  $10^6$  or more polypeptides. Advantageously, smaller repertoires comprise between  $10$  and  $10^4$  polypeptides.

In the present invention, two or more repertoires of polypeptides are screened against each other. Advantageously, at least 50% of the members of each repertoire are screened against each other in each screen. Preferably, 60%, 70%, 80%, 90%, 95% or even 100% of the members of each repertoire are so screened.

In the context of the present invention, "interact" refers to any detectable interaction between the molecules which comprise the various repertoires and, optionally, any additional molecules that comprise the screen. For example, in the case of antibody-antigen interactions one repertoire might comprise a diverse population of antibodies and the other a diverse population of antigens, the interaction being a binding interaction. Alternatively, the interaction may be an enzymatically-catalysed reaction, in which one repertoire is composed of enzymes and the other repertoire is composed of therefor. Any interaction may be assayed using the present invention, including binding interactions, DNA methylation, nucleic acid degradation, nucleic acid cleavage (single or double stranded), signalling events, catalytic reactions, phosphorylation events, glycosylation events, proteolytic cleavage, chemical reactions, cellular infection and combinations thereof. The detection of such interactions is well known in the art.

In the context of the present invention, "molecule" refers to any substance which can be applied to the screen. Such molecules may include peptides, polypeptides, nucleic acid molecules, purified proteins, recombinant proteins, amino acids, cDNAs, expressed cDNAs, oligonucleotides, nucleotides, nucleotide analogues, families of related genes or

the corresponding proteins thereof, enzymes, DNA binding proteins, immunoglobulin family members, antibodies, T cell receptors, haptens, small organic molecules, non-organic compounds, metal ions, carbohydrates and combinations thereof. The creation of repertoires of such molecules is well known in the art. "Polypeptides" may refer to polypeptides such as expressed cDNAs, members of the immunoglobulin superfamily, such as antibody polypeptides or T-cell receptor polypeptides. Advantageously, antibody repertoires may comprise repertoires comprising both heavy chain ( $V_H$ ) and light chain ( $V_L$ ) polypeptides, which are either pre-assembled or assembled and screened according to the present invention. An antibody polypeptide, as used herein, is a polypeptide which either is an antibody or is a part of an antibody, modified or unmodified. Thus, the term antibody polypeptide includes a heavy chain, a light chain, a heavy chain-light chain dimer, a Fab fragment, a  $F(ab')_2$  fragment, a Dab fragment, a light or heavy chain single domain, and an Fv fragment, including a single chain Fv (scFv) or a di-sulphide bonded Fv (dsFv). Methods for the construction of such antibody molecules and nucleic acids encoding them are well known in the art. However, "polypeptides" may refer to other polypeptides, such as enzymes, antigens, drugs, molecules involved in cell signalling, such as receptor molecules, or one or more individual domains of larger polypeptides, which are capable of an interaction with a target molecule. Molecules according to the invention may be provided in cellular form, that is in the form of cells producing a molecule as described above, or in non-cellular form, that is not contained within cells. Cells may be, for example, bacterial cells or mammalian cells. The use of yeast cells is also envisaged.

"Juxtaposition", in the context of the present invention, includes but is not limited to physical contact. Two or more repertoires according to the invention may be juxtaposed such that the molecules are capable of interacting with one another in such a manner that the sites of interactions between the members of the repertoires can be correlated with their position. Alternatively, the repertoires may be juxtaposed with one another and with a target molecule such that the members of the repertoires interact with one another and then together interact with a target molecule.

An "array" as referred to herein, is a pre-determined spatial arrangement of the members of the repertoire. The array may take any physical form. The array can be created by manual or automated means and preferred arraying technologies are further described below.

A "dispensing event" is a single event whereby a substance is transferred from one discrete location to a second discrete location. A discrete location may be in the form of a

well, a tube, a channel, a spot, a line, a rectangle, a sphere, a cube etc. Examples of single dispensing events include:

- (i) pipetting a liquid from one tube or well to a second tube or well. In this case pipetting aliquots of the same liquid into multiple tubes or wells would be considered to be multiple dispensing events, as would dispensing two or more different liquids into the same tube or well. or
- (ii) transferring liquid from a source well to a membrane by pin transfer to create a spot of that liquid. In this case spotting a second aliquot from the same source well onto a different destination location on the membrane would be considered a separate dispensing event. or
- (iii) transferring liquid from a single source well to create a single continuous line of liquid on a membrane. In this case creating a second separate line, even of the same liquid, would be considered a separate dispensing event. or
- (iv) dispensing a solution down a tube or channel. In this case, dispensing a different solution down the same tube or channel, or the same solution down a different tube or channel would be considered a separate dispensing event.

A "matrix" in the context of the present invention, is a particular kind of array which can be used to study all possible interactions between all the members in two or more repertoires of molecules. Such matrices may comprise a series of intersecting lines, channels or tubes, each containing one or more members of the repertoires. A single matrix will contain many individual lines, channels or tubes and many more intersections, or nodes.

25

### **Brief Description of the Drawings**

**Figure 1:** Outline of one method for screening a repertoire of antibodies against a repertoire of antigens according to the present invention, demonstrating how hundreds of different antibodies could be screened simultaneously against hundreds of different antigens to identify interacting pairs. Specific interactions are indicated.

**Figure 2:** Analysis of scFvs using a manually created matrix. Here, 21 antigens (horizontally) are screened against 16 scFvs (vertically). Four scFvs have been selected against ubiquitin by phage selection (Ub1b1, Ub1a1, R13 and R14). Two antigen clones are known to be ubiquitin (Q and T) and five other clones (A, P, R, S and U) have been identified in a primary screen as probably binding an anti-ubiquitin scFv. Each of the four anti ubiquitin scFvs binds the two known ubiquitin clones and each of the five potential

ubiquitin clones. However, it can be seen that scFv Ub1b1 and scFv R14 are highly cross reactive.

**Figure 3:** A head for robotic line drawing according to the present invention designed for mounting on a robotic platform which allows movement in x, y and z dimensions. A row of fountain pen nibs delivers repertoire members in a liquid suspension, by capillary action to a suitable solid support. The nibs are mounted in such a way as to deliver liquid at an optimum angle to the solid support and then to be held vertical by a stop for loading with liquid from a 96 well microtitre plate.

**Figure 4:** Analysis of scFvs using a robotically created matrix. Double lines of 12 antigens (horizontally) are screened against 192 scFvs (vertically). Specific interactions can be observed at the intersections of specific pairings. In addition, scFvs that cross-react with the nitrocellulose can be seen as continuous horizontal lines as can scFvs that cross-react with all antigens (horizontal spotting).

**Figure 5:** Example of creation and screening of a two-chain antibody repertoire. (a) A spotted array according to the prior art. Bacteria that secrete 1. Bovine Serum Albumin (BSA) binding heavy chains, 2. BSA binding light chains, 3. non binding heavy and light chains or 4. BSA binding heavy and light chains were mixed and then grown and induced in close proximity to immobilised BSA indicating that 1 and 2 need to be mixed to get a binding antibody (as seen in the control, 4). 32 separate dispensing events were required to produce this screen. (b) A matrix screen according to the present invention allows the same screen to be performed using only 8 dispensing events (the lack of a signal for 1 down with 2 across is probably due to a bubble being present between the filters during induction).

### Detailed Description of the Invention

Matrices according to the present invention can be generated in many different ways to screen many different interactions involving many different molecules. The invention is characterised by the ability to screen all combinations of members of two or more repertoires. We have shown that this can be performed using a series of intersecting lines, but other approaches which allow combinatorial screening of two or more repertoires using a minimum number of dispensing events are envisaged, such as the use of intersecting channels or tubes. Our method relies on the juxtaposition of continuous groupings of molecules to create a web in two or three dimensions whereby members of the different repertoires come together and potentially interact with one another. This

contrasts with screening protocols in the prior art, whereby discontinuous spotting or compartmentalised wells are used to segregate individual combinations of molecules. In the present invention, continuous lines, channels or tubes intersect one another such that individual combinations of molecules exist at their points of intersection, or nodes. Taken  
5 as a whole, the molecular 'web' or 'network' thereby created can be used not only to identify specific interacting pairs, but also the overall pattern of interactions between two repertoires. The information so provided can be used to compare the performance of members of either of the repertoires with one another and in particular can be used to rapidly identify cross-reactivities of individual repertoire members within the matrix.

### 10 Repertoires for screening

Many different repertoires can may be used with the present invention, the construction of which is well known by those skilled in the art. Repertoires of small organic molecules  
15 may be constructed by methods of combinatorial chemistry. Repertoires of peptides can be synthesised on a set of pins or rods, such as described in WO84/03564. A similar method involving peptide synthesis on beads, which forms a peptide repertoire in which each bead is an individual repertoire member, is described in U.S. Patent No. 4,631,211 and a related method is described in WO92/00091. A significant improvement of the  
20 bead-based methods involves tagging each bead with a unique identifier tag, such as an oligonucleotide, so as to facilitate identification of the amino acid sequence of each library member. These improved bead-based methods are described in WO93/06121. Although these repertoires could be constructed prior to arraying to produce the matrix, it is envisaged that all the techniques described above could be adapted for *in situ* synthesis  
25 of the repertoire members directly on the matrix itself - thus linking repertoire construction and repertoire screening according to the present invention. Indeed, another chemical synthesis method involves the synthesis of arrays of peptides (or peptidomimetics) on a surface in a manner that places each distinct library member (e.g., unique peptide sequence) at a discrete, predefined location in the array. The identity of  
30 each library member is therefore determined by its spatial location in the array. The locations in the array where binding interactions between a predetermined molecule (e.g., a receptor) and reactive library members occur is determined, thereby identifying the sequences of the reactive library members on the basis of spatial location. These methods are described in U.S. Patent No. 5,143,854; WO90/15070 and WO92/10092; Fodor *et al.*  
35 (1991) *Science*, **251**: 767; Dower and Fodor (1991) *Ann. Rep. Med. Chem.*, **26**: 271 and could be easily be adapted for creation of matrices according to the present invention.

The present invention is especially useful for the screening of protein-protein interactions, particularly antibody-antigen interactions. The preparation of appropriate antibody repertoires useful in the present invention is described in WO 99/20749, the disclosure of which is incorporated herein by reference. WO 99/20749 describes how a library of immunoglobulins may be prepared and preselected using a generic ligand, and/or prepared using a single main-chain conformation. Libraries as described in WO 99/20749 can be expressed in host organisms, as described therein or according to techniques well known in the art, to produce repertoires of polypeptides which are suitable for arraying and use in the present invention. Alternatively, polypeptides may be synthesised *in situ* for use in the present invention, or expressed using *in vitro* transcription/translation.

#### **Arraying members of the repertoires to create the matrix screen**

According to the present invention, molecules may be arrayed by any one of a variety of methods, manual or automated, in order to create a matrix, depending upon whether the molecules are arrayed as such or expressed by arrayed nucleotide precursors, which may or may not be present in host cells. Arrays are advantageously created by robotic means, since robotic techniques allow the creation of precise and condensed matrices, which can be easily replicated so that, for example, a combinatorial antibody repertoire created according to the invention can be screened against many different target ligands. Robotic platforms are well-known in the art, and machines are available from companies such as Genetix, Genetic MicroSystems and BioRobotics which are capable of arraying at high speed with great accuracy over small or large surfaces. Such machines are capable of spotting purified protein, supernatant or cells onto porous or non-porous surfaces, such that they can subsequently be fixed thereto if necessary to produce stable arrays. Although robotic manipulation is the preferred method for creating high density arrays, any technique, including manual techniques, which is suitable for locating molecules or cells at pre-defined locations on a support, may be used. Arraying may be regular, such that lines are 'drawn' at a given distance from the next, irregular or random.

30

The repertoires of molecules may be screened in solution for interactions or one or more of the repertoires may be immobilised on a solid support. Thus, two solutions may flow down two channels such that at their point of intersection an interaction occurs which can be detected by, for example, a colorimetric, fluorescent, or luminescent reaction. Alternatively, one of the repertoires could be immobilised on a nitrocellulose membrane by, for example, cross-linking and then solutions corresponding to a second repertoire could be 'drawn' onto the support harbouring the immobilised members of the first repertoire. Such immobilisation may be direct or indirect. For example, indirect

35

immobilisation may involve arraying a polypeptide repertoire onto a solid support coated with a generic ligand. Alternatively, both repertoires could be immobilised on a separate solid supports and then juxtaposed to identify interacting pairs. In a preferred aspect of the invention, matrices of polypeptides may be created by first arraying their nucleic acid precursors in host cells and then by expressing the nucleotide sequences to produce the corresponding polypeptides.

#### Use of molecules selected according to the invention

Molecules selected according to the method of the present invention may be employed in substantially any process. Where the molecules are polypeptides, they may be used in any process which involve binding or catalysis, including *in vivo* therapeutic and prophylactic applications, *in vitro* and *in vivo* diagnostic applications, *in vitro* assay and reagent applications, and the like. For example, antibody molecules may be used in antibody based assay techniques, such as ELISA techniques, Western blotting, immunohistochemistry, affinity chromatography and the like, according to methods known to those skilled in the art.

As alluded to above, the molecules selected according to the invention are of use in diagnostic, prophylactic and therapeutic procedures. For example, enzyme variants generated and selected by these methods may be assayed for activity, either *in vitro* or *in vivo* using techniques well known in the art, by which they are incubated with candidate substrate molecules and the conversion of substrate to product is analysed. Selected cell-surface receptors or adhesion molecules might be expressed in cultured cells which are then tested for their ability to respond to biochemical stimuli or for their affinity with other cell types that express cell-surface molecules to which the undiversified adhesion molecule would be expected to bind, respectively.

Therapeutic and prophylactic uses of proteins prepared according to the invention involve the administration of polypeptides selected according to the invention to a recipient mammal, such as a human. Of particular use in this regard are antibodies, other receptors (including, but not limited to T-cell receptors) or binding protein thereof.

Substantially pure molecules of at least 90 to 95% homogeneity are preferred for administration to a mammal, and 98 to 99% or more homogeneity is most preferred for pharmaceutical uses, especially when the mammal is a human. Once purified, partially or to homogeneity as desired, the selected polypeptides may be used diagnostically or therapeutically (including extracorporeally) or in developing and performing assay



procedures, immunofluorescent staining and the like (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Volumes I and II, Academic Press, NY).

The selected antibodies or binding proteins thereof of the present invention will typically find use in preventing, suppressing or treating inflammatory states, allergic hypersensitivity, cancer, bacterial or viral infection, and autoimmune disorders (which include, but are not limited to, Type I diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease and myasthenia gravis).

In the instant application, the term "prevention" involves administration of the protective composition prior to the induction of the disease. "Suppression" refers to administration of the composition after an inductive event, but prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after disease symptoms become manifest.

Animal model systems which can be used to screen the effectiveness of the antibodies or binding proteins thereof in protecting against or treating the disease are available. Methods for the testing of systemic lupus erythematosus (SLE) in susceptible mice are known in the art (Knight *et al.* (1978) *J. Exp. Med.*, **147**: 1653; Reinersten *et al.* (1978) *New Eng. J. Med.*, **299**: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by inducing the disease with soluble AchR protein from another species (Lindstrom *et al.* (1988) *Adv. Immunol.*, **42**: 233). Arthritis is induced in a susceptible strain of mice by injection of Type II collagen (Stuart *et al.* (1984) *Ann. Rev. Immunol.*, **42**: 233). A model by which adjuvant arthritis is induced in susceptible rats by injection of mycobacterial heat shock protein has been described (Van Eden *et al.* (1988) *Nature*, **331**: 171). Thyroiditis is induced in mice by administration of thyroglobulin as described (Maron *et al.* (1980) *J. Exp. Med.*, **152**: 1115). Insulin dependent diabetes mellitus (IDDM) occurs naturally or can be induced in certain strains of mice such as those described by Kanasawa *et al.* (1984) *Diabetologia*, **27**: 113. EAE in mouse and rat serves as a model for MS in human. In this model, the demyelinating disease is induced by administration of myelin basic protein (see Paterson (1986) *Textbook of Immunopathology*, Mischer *et al.*, eds., Grune and Stratton, New York, pp. 179-213; McFarlin *et al.* (1973) *Science*, **179**: 478; and Satoh *et al.* (1987) *J. Immunol.*, **138**: 179).

The selected antibodies, receptors (including, but not limited to T-cell receptors) or binding proteins thereof of the present invention may also be used in combination with other antibodies, particularly monoclonal antibodies (MAbs) reactive with other markers on human cells responsible for the diseases. For example, suitable T-cell markers can

include those grouped into the so-called "Clusters of Differentiation," as named by the First International Leukocyte Differentiation Workshop (Bernhard *et al.* (1984) *Leukocyte Typing*, Springer Verlag, NY).

- 5 Generally, the present selected antibodies, receptors or binding proteins will be utilised in purified form together with pharmacologically appropriate carriers. Typically, these carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, any including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable
- 10 physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.

- Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers,
- 15 such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) *Remington's Pharmaceutical Sciences*, 16th Edition).

- The selected polypeptides of the present invention may be used as separately
- 20 administered compositions or in conjunction with other agents. These can include various immunotherapeutic drugs, such as cyclosporine, methotrexate, adriamycin or cisplatinum, and immunotoxins. Pharmaceutical compositions can include "cocktails" of various cytotoxic or other agents in conjunction with the selected antibodies, receptors or binding proteins thereof of the present invention, or even combinations of selected polypeptides
- 25 according to the present invention having different specificities, such as polypeptides selected using different target ligands, whether or not they are pooled prior to administration.

- The route of administration of pharmaceutical compositions according to the invention
- 30 may be any of those commonly known to those of ordinary skill in the art. For therapy, including without limitation immunotherapy, the selected antibodies, receptors or binding proteins thereof of the invention can be administered to any patient in accordance with standard techniques. The administration can be by any appropriate mode, including parenterally, intravenously, intramuscularly, intraperitoneally, transdermally, *via* the
- 35 pulmonary route, or also, appropriately, by direct infusion with a catheter. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician.

The selected polypeptides of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immunoglobulins and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of antibody activity loss (e.g. with conventional immunoglobulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted upward to compensate.

The compositions containing the present selected polypeptides or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an adequate amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective dose". Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from 0.005 to 5.0 mg of selected antibody, receptor (e.g. a T-cell receptor) or binding protein thereof *per* kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For prophylactic applications, compositions containing the present selected polypeptides or cocktails thereof may also be administered in similar or slightly lower dosages.

A composition containing a selected polypeptide according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal. In addition, the selected repertoires of polypeptides described herein may be used extracorporeally or *in vitro* selectively to kill, deplete or otherwise effectively remove a target cell population from a heterogeneous collection of cells. Blood from a mammal may be combined extracorporeally with the selected antibodies, cell-surface receptors or binding proteins thereof whereby the undesired cells are killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.

The invention is further described, for the purpose of illustration only, in the following examples.

### Example 1

#### Matrix Screening of a scFv Repertoire

The two filter capture system used as part of the present example is based upon that described in our co-pending UK patent application entitled "Array Screening Method", (UK Patent Application Number: 9928787.2). Bacteria are grown in lines on one filter and the scFvs thereby produced are captured on a second filter that has lines of antigen bound to the nitrocellulose, which are oriented at 90° from those lines of scFv on the first filter (see Fig 1). At intersections where scFv interacts with antigen, the scFv is captured if the antigen and scFv bind. In this example, detection of bound scFv is performed with superantigen Protein L conjugated to HRP.

#### Methods

##### 15 *Antigen library*

The antigens are from human expression library hEX1, prepared from foetal brain poly(A)+ RNA by oligo(dT)-priming (Büssow et al 1998). cDNAs are cloned directionally in a modified pQE-30 vector (Qiagen).

##### 20 *Antigen filters*

Antigen clones were grown overnight in liquid culture (2xTY containing 100 µg/ml Amp, and 1 % glucose) at 37 °C. For manual line drawing, liquid cultures were transferred to a pre-wetted PVDF filter (soak in ethanol, rinse in PBS and dip in 2xTY) by drawing along the filter against a metal ruler with a p10 filter tip (Art) not mounted on a pipette. Thus, the capillary action of the tip was used for delivery of the liquid onto the surface of the membrane. Each clone was drawn onto the filter 6 mm from the previous one. For automated line drawing, liquid cultures were transferred to a PVDF filter using the robotic head depicted in Fig 3 attached to a Kaybee Systems picker/gridder system. Each clone was drawn onto the filter 4.5mm mm from the previous one at a speed of 25 mm/s.

30

The antigen filters were then grown overnight on TYE agar plates containing 100 µg/ml Amp, 1 % glucose at 30 °C. The filter was then transferred to another TYE agar plate containing 100 µg/ml Amp, 1mM IPTG for 3h at 37 °C for induction of the clones. Antigen filters were removed from the plate and denatured on pre-soaked blotting paper containing 0.5M NaOH, 1.5 M NaCl for 10 min, neutralised for 2 x 5 min in 1M Tris-HCl, pH7.5, 1.5M NaCl and incubated for 15 min in 2 x SSC. Filters were dried, soaked briefly in ethanol and then blocked in 4 % Marvel PBS, rinsed in PBS and dipped in 2xTY.

35

### *ScFv library*

The scFvs are from a library based on a single human framework for V<sub>H</sub> (V3-23/DP-47 and J<sub>H</sub>4b) and V<sub>K</sub> (O12/O2/DPK9 and J<sub>K</sub>1), with side chain diversity (NNK or DVT encoded) incorporated at positions in the antigen binding site that make contacts to antigen in known structures and are highly diverse in the mature repertoire. The fold that is used is frequently expressed *in vivo*, and binds to the generic ligands Protein L and A, which facilitate capture or detection of the scFvs but do not interfere with antigen binding. The scFv clones have been pre-screened in scFv format for binding to Protein A and Protein L to ensure that they were functional.

### *ScFv filter*

Antibody clones were grown overnight in liquid culture (2xTY containing 100 µg/ml ampicillin and 1% glucose) at 37°C. Liquid cultures were then transferred to a pre-blocked nitrocellulose filter (4% skimmed milk powder in PBS for 1 hour at room temperature (RT), rinse in PBS and dip in 2xTY). Manual and robotic transfer of antibodies to the filter was performed as for the antigen cultures, except that the density of scFvs lines created by robotic transfer was one every 1.125 mm.

ScFv filters were then grown on TYE agar plates containing 100 µg/ml Amp, 1 % glucose at 37 °C. After overnight growth the antigen filter was placed onto a fresh TYE agar plate 100 µg/ml Amp, 1mM IPTG, dried, and then the scFv filter was placed on top of this. The plate with the two filters was then incubated for 3h at 30 °C for induction of the scFvs.

### *Probing of filters*

The top (scFv) filter was discarded and the second (antigen) filter was washed 3 x with PBS/0.05% Tween (PBST) and blocked with 4% MPBS for 30 min at RT. The filters were washed 3x with PBST and then incubated with a Protein L HRP conjugate (Actigen, 1/2000) in 4% MPBS for 1 hr at RT. Filters were then washed a further three times with PBST and developed with ECL reagent. All incubations were performed in 50 ml of buffer on a gently agitating shaker.

## **Results**

As a model system, we performed a manual matrix screen of 21 antigens against 16 scFvs, resulting in 336 interactions being tested using only 37 dispensing events. Included in the scFv repertoire were four scFvs that had been selected against ubiquitin by phage selection (Ub1b1, Ub1a1, R13 and R14). Included in the antigen repertoire were two

clones known to be ubiquitin (Q and T) and five other clones (A, P, R, S and U) that had been identified in a primary screen as probably binding an anti ubiquitin scFv. As can be seen (Fig 2), each of the four anti ubiquitin scFvs bound the two known ubiquitin clones and each of the five potential ubiquitin clones. However, it can be seen that scFv Ub1b1 and scFv R14 are highly cross reactive. Also included in the model array were 14 antigen clones identified in a primary antigen array screen as possible binders to twelve scFv clones C2 to H11. As can be seen from the matrix (Fig 2), antigen M (a protein of unknown function) binds specifically to scFv D12. Also antigen E, (a DNA binding protein) binds specifically to scFv H11. This demonstrates the utility of the matrix screen in confirming interactions originally identified in an antigen array screen.

We then moved to a higher density matrix screen, using a robotic head (Fig 3) to draw the lines. In this system double lines of 12 antigens (horizontally) are screened against 192 scFvs (vertically). Thus, 2304 different potential interactions were tested each twice over using only 216 dispensing events. Again many different interactions are observed at the intersections of the lines, particularly against three antigens (two of which are the same).

### Example 2

#### Creation and screening of a two-chain antibody repertoire according to the present invention

The two filter capture system used as part of the present example is based upon that described in our co-pending UK patent application entitled "Array Screening Method", (UK Patent Application Number: 9928787.2). Bacteria expressing either a Bovine Serum Albumin (BSA) binding heavy chain (1), a BSA binding light chain (2), non binding heavy and light chains (3) or BSA binding heavy and light chains (4) were either mixed and grown as spots (Figure 5a) or drawn as horizontal and vertical lines and then grown (Figure 5b). In both cases, after overnight growth the filters harbouring the grown bacteria were laid on top of a second filter coated with BSA and then induced for protein expression. Only in those cases where a binding heavy chain is co-expressed with a binding light chain is a positive signal observed (i.e. 1 and 2 together or any combination involving 4. The lack of a signal for 1 down with 2 across is probably due to a bubble being present between the filters during induction). The drawing of lines dramatically reduces the number of dispensing events (in this case from 32 to 8). If the screen were to be increased to cover 1000 heavy chains versus 1000 light chains the number of dispensing events would be reduced from 2 million to 2 thousand by using the method according to the present invention.

## Claims

1. A method for screening a first repertoire of molecules against a second repertoire of molecules to identify those members of the first repertoire which interact with  
5 members of the second repertoire, comprising :
  - (b) arranging the first and second repertoires to form at least one array, such that all members of the first repertoire are juxtaposed to all members of the second repertoire; and
  - (b) detecting the interaction/s between the members of the first and second  
10 repertoires.
2. A method according to claim 1, wherein members of the both the first repertoire and the second repertoire are arranged in a series of lines, channels or tubes, each containing a member of the first or second repertoires such that the lines, channels or  
15 tubes corresponding to the first repertoire and those corresponding to the second repertoire are juxtaposed to one another so that all members of the first repertoire are juxtaposed with all members of the second repertoire.
3. A method according to claim 2, wherein each line, channel or tube comprises a  
20 group of different members of the first and second repertoires, respectively.
4. A method according to any preceding claim, wherein members of the first and second repertoires are run along channels cut or etched into a solid material such that all the channels containing members of the first repertoire intersect all the channels  
25 containing members of the second repertoire.
5. A method according to any one of claims 1 to 3, wherein members of the first and second repertoires are applied to a single support.
- 30 6. A method according to any one of claims 1 to 3, comprising the steps of:
  - (a) arranging the first and second repertoires on first and second supports;
  - (b) juxtaposing the first and second supports such that all members of the first repertoire are juxtaposed with all members of the second repertoire; and
  - (c) detecting the interactions between the members of the first and second repertoires.
- 35 7. A method according to any preceding claim, wherein the first and second repertoires are selected from the group consisting of repertoires of: peptides; polypeptides; nucleic acid molecules; purified proteins; recombinant proteins; amino

acids; cDNAs; expressed cDNAs; oligonucleotides; nucleotides; nucleotide analogues; families of related genes or the corresponding proteins thereof; enzymes; DNA binding proteins; immunoglobulin family members; antibodies; T cell receptors; haptens; small organic molecules; non-organic compounds; metal ions; and carbohydrates.

5

8. A method according to any preceding claim, wherein the interaction between the members of the first and second repertoires is selected from the group consisting of: a binding interaction; DNA methylation; nucleic acid degradation; nucleic acid cleavage (single or double stranded); a signalling event; a catalytic reaction; a phosphorylation event; a glycosylation event; proteolytic cleavage; a chemical reaction; and cellular infection.

15

9. A method for screening first, second and third repertoires of molecules against each other to identify those members of the first, second and third repertoires which interact, comprising :

- (a) arranging the first, second and third repertoires to form at least one array, such that all members of the first, second and third repertoires are juxtaposed; and
- (b) detecting the interaction/s between the members of the first, second and second repertoires.

20

10. A method for creating and screening a combinatorial library of two-chain polypeptides, each of which comprises one member of a first repertoire and one member of a second repertoire, which method comprises:

- (a) arranging the first and second repertoires, such that all members of the first repertoire intersect all members of the second repertoire, thereby generating at their intersections all combinations of functional two-chain polypeptides; and optionally
- (b) detecting the interaction between the two-chain polypeptides and a target molecule.

30

11. A method according to claim 10, wherein the combinatorial library so produced is screened for interactions with more than one target molecule.

35

12. A method according to claim 10 or claim 11, wherein a three-chain polypeptide library is created (and optionally screened) using first, second and third repertoires of molecules in three dimensions.

13. A method according to any preceding claim, whereby the pattern of interactions between the first, second (and optionally third) repertoires is used to identify positive



interactions, negative interactions, specific interactions or cross-reactive interactions, or is used to construct a phylogenic tree inferring the similarity between members of the first repertoire (using the pattern of interactions with the second and/or, optionally third, repertoires), of the second repertoire (using the pattern of interactions with the first and/or, optionally third, repertoires) and/or of the third repertoire (using the pattern of interactions with members the first and/or second repertoires).

14. A method according to any preceding claim, whereby one or more of the first, second and, optionally, third repertoires comprise a plurality of nucleic acid molecules which are expressed to produce their corresponding polypeptides *in situ* in the array.

15. A method according to claim 14, wherein the nucleic acid molecules are in the form of expression vectors which encode the members of the repertoire of polypeptides operatively linked to control sequences sufficient to direct their transcription.

16. A method according to claim 15, wherein the expression vector is a bacteriophage.

17. A method according to claim 16, wherein the expression vector is a plasmid.

18. A method according to claim 16, wherein the expression vector is a linear nucleic acid molecule.

19. A method according to any one of claims 14 to 18, wherein the nucleic acids are contained and expressed within cells.

20. A method according to claim 19, wherein the cells are selected from the group consisting of bacterial cells, lower eukaryotic cells and higher eukaryotic cells.

21. A method according to any one of claims 14 to 18 (inclusive), wherein the nucleic acid molecules are immobilised in the form of naked or complexed nucleic acid.

22. A method according to any previous claim, wherein the repertoire members are arrayed using robotic means.

23. A method for screening a first repertoire of molecules against a second repertoire of molecules to identify those members of the first repertoire which do not interact with those members of the second repertoire, comprising :

- (a) arranging the first and second repertoires, such that all members of the first repertoire are juxtaposed with all members of the second repertoire; and
- (b) identifying those members of the first and second repertoires that do not interact with one another.

5

24. A method for screening a first repertoire of molecules against a second repertoire of molecules to identify members of the first and second repertoires whose interactions with one another are dependant on the presence or absence of a third molecule or set of molecules, comprising:

- 10 (a) arranging the first and second repertoires, such that all members of the first repertoire are juxtaposed with all members of the second repertoire; and
- (b) detecting the interactions between members of the first repertoire and the members of the second repertoire in the presence of different concentrations of the third molecule or set of molecules.

15

25. A method according to claim 24, wherein the third molecule or set of molecules interacts with certain members of the first repertoire, thereby enabling those members of the first repertoire to interact with certain members of the second repertoire.

- 20 26. A method according to claim 24, wherein the interactions between the members of the first and second repertoire require the simultaneous binding of these members to the third molecule or set of molecules.

- 27. A method according to claim 24, wherein the interactions between the members of  
25 the first and second repertoire are enhanced by the presence of a third molecule or set of molecules.

- 28. A method according to claim 24, wherein the interactions between the members of  
30 the first and second repertoire are blocked by the presence of a third molecule or set of molecules.

29. An apparatus for drawing high density lines comprising members of the first, second and, optionally third repertoire of molecules.

- 35 30. An apparatus which comprises intersecting channels or tubes along which members of the first, second and, optionally third repertoire of molecules can pass.

31. A method according to claim 1, wherein fewer dispensing events are required than the number of interactions to be tested.


5 32. A method according to claim 31, wherein members of one but not all repertoires are arranged in a series of lines, channels or tubes, each containing a member of that repertoire such that the lines, channels or tubes corresponding to that repertoire intersect with all members of the other repertoires, howsoever arranged.

10 33. A method according to claim 32 wherein members of the both the first repertoire and the second repertoire are arranged in a series of lines, channels or tubes, each containing a member of the first or second repertoires such that the lines, channels or tubes corresponding to the first repertoire and those corresponding to the second repertoire are contacted with one another so that more interactions are tested than there were dispensing events.

**Abstract**

The invention concerns a method which can be used to screen two or more repertoires of molecules against one another and/or to create combinatorial repertoires by combining  
5 two or more repertoires. In particular, the invention relates to a method whereby two repertoires of molecules can be screened such that all members of the first repertoire are tested against all members of the second repertoire for functional interactions. Furthermore, the invention relates to the creation and screening of antibody repertoires by combining a repertoire of heavy chains with a repertoire of light chains such that  
10 antibodies formed by the all combinations of heavy and light chains can be screened against one or more target ligands.

Antibodies drawn  
as lines on top filter



Antigens drawn as lines  
on bottom filter

Figure 1




Figure 2






Figure 3




Figure 4








Figure 5a




Figure 5b

